Schering-Plough Extends Antibody Alliance With MorphoSys - Third Extension With Major Pharmaceutical Company After Landmark Deal With Novartis

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced that Schering-Plough Corporation has decided to extend the current collaboration between the two companies for one year. The collaboration, announced in May 2006, has a maximum term of 5 years until 2011 and may be extended by Schering-Plough after each single year.

More: continued here

Filed under: Infectious Diseases / Bacteria / Viruses on May 22nd, 2008